P&G Health Q4 FY26: PAT up 55%, stock up 12% after results

Stock reaction: sharp jump and a new intraday high

Procter & Gamble Health (P&G Health) saw a strong move in its share price after reporting its Q4 FY26 earnings. One market update showed the stock rising 12.17% to ₹6,339.65. Another update in the same set of reports indicated the stock was trading 10.50% higher at ₹6,245.00 versus a previous close of ₹5,651.65.

The rally was also reflected in intraday data shared by market trackers. The stock traded in a band of ₹6,701.40 and ₹5,865.55 during the session mentioned in the feed. A separate Hindi-language report said the stock rose more than 15% and touched an intraday high around ₹6,700 after the quarterly results.

What triggered the move: Q4 FY26 earnings surprise

The jump followed a “strong set” of Q4 FY26 numbers from the vitamins, minerals and supplements maker. The earnings prints across multiple reports broadly pointed to higher profit growth, a sharp improvement in operating profit (EBITDA), and a meaningful expansion in margins.

While the market reaction was immediate, the underlying driver was the year-on-year profit acceleration in the March 2026 quarter. Investors also tracked the board’s dividend recommendation alongside the quarterly financials.

Q4 FY26 profit: PAT up 54.63% YoY to ₹94.60 crore

For Q4 FY26, the company’s standalone net profit rose 54.63% year-on-year (YoY) and 21.92% quarter-on-quarter (QoQ) to ₹94.60 crore. Another report described the same quarter’s PAT as ₹95 crore, up about 55% YoY.

The same information set also provided a prior-year comparison point, stating profit rose to ₹94.6 crore from ₹61.2 crore in Q4 FY25. The consistency across reports supported the market’s view that the quarter delivered stronger profitability versus the base period.

Q4 FY26 revenue: operations rise about 19% YoY

Revenue from operations for the March 2026 quarter was reported at ₹370.45 crore, up 19.12% YoY, compared with ₹310.99 crore in the corresponding quarter last year. Another report rounded this to ₹370 crore versus ₹311 crore.

One earnings summary also cited quarterly sales of ₹365 crore, up 20% compared to last year, attributing the increase to strong brand fundamentals and a positive consumer response to new innovations. Taken together, these data points indicated that top-line growth remained a key element of the Q4 narrative.

Operating performance: EBITDA up to about ₹135 crore and margin expands

Operating profitability improved sharply in Q4 FY26. The company’s EBITDA was reported at ₹135.6 crore versus ₹80.9 crore in the year-ago quarter, a jump of 67.6% YoY.

Another report cited EBITDA at about ₹135 crore versus about ₹81 crore in Q4 FY25. Along with this, EBITDA margin expanded to about 36.60% (also reported as 36.57%), compared with 26.02% in the year-ago period. A Hindi report described the margin move from 26% to 37%, reflecting the same direction and magnitude of change.

PBT in Q4 FY26: ₹133.21 crore, up both QoQ and YoY

Profit before tax (PBT) in Q4 FY26 stood at ₹133.21 crore. This was reported as up 22.41% versus Q3 and up 69.63% versus Q4 FY25.

The PBT growth helped explain why the quarter’s bottom line expanded at a faster pace than revenue. For market participants, this combination of growth and margin expansion is typically central to assessing whether a rally is earnings-led.

Full-year FY26: strong year, but figures vary across reports

For the full year ended March 31, 2026, one report stated net sales surged 50.72% to ₹1,407.97 crore from ₹934.17 crore in the previous year. Over the same period, PBT rose 44.36% to ₹449.86 crore and profit after tax (PAT) climbed 39.46% to ₹326.91 crore.

Another report in the provided feed stated the company closed FY26 with reported sales of ₹1,385 crore and PAT of ₹327 crore, reflecting growth of 16% and 30%, respectively. Both sets of annual PAT numbers are closely aligned around ₹327 crore, while the annual sales figure differs between the reports.

Dividend: board recommends ₹45 final dividend; total ₹205 for FY26

Alongside the results, the board of directors recommended a dividend of ₹45 per equity share (face value ₹10 each) for the financial year ended March 31, 2026. A Hindi report added that the company had already announced an interim dividend and a special dividend during FY26.

As per that report, the total dividend for FY26 works out to ₹205 per share when the interim, special, and proposed final dividend are combined. The final dividend still requires shareholder approval, and the company planned to pay it on or before September 25, 2026, subject to approval.

Snapshot table: key reported numbers (Q4 FY26 and FY26)

Market context: valuation and peers mentioned by trackers

One market snapshot included valuation and peer comparison data. It reported a trailing twelve-month (TTM) P/E ratio of 31.99 for P&G Health compared with a sector P/E of 25.68.

The same feed listed peers such as Sun Pharmaceutical Industries, Torrent Pharmaceuticals, and Dr Reddy’s Laboratories in a “listed peers” section. It also noted the stock’s recent performance as 0.03% for the year and 5.84% over the last five days (as per the cited market tracker).

Why the results mattered for investors

The core takeaway from the quarter was the scale of profit growth relative to revenue growth. With revenue up around 19% YoY and EBITDA up about 67% YoY, the numbers implied significant operating leverage in Q4 FY26, reflected in the margin expansion from about 26% to about 36.6%.

The dividend messaging added another layer for income-focused investors, particularly given the stated FY26 total dividend of ₹205 per share (including interim and special dividends, plus the proposed final dividend). Separately, the variation in reported full-year sales growth rates across the feed highlighted the importance of tracking the company’s final, filed financial statements for the definitive annual revenue base.

Conclusion: earnings-led move with dividends in focus

P&G Health’s post-results rally followed a quarter marked by a steep rise in PAT to about ₹95 crore, strong growth in operating profit to about ₹135 crore, and a sharp improvement in EBITDA margin to about 36.6%. The board’s recommendation of a ₹45 final dividend, and the reported FY26 total dividend of ₹205 per share, remained a key point of attention.

Next, investors are likely to track the shareholder approval process for the final dividend and the company’s stated timeline to pay it on or before September 25, 2026, subject to approval.